Blue Plans will now have an additional home delivery option that they can choose to offer their members.
Prime Therapeutics has launched MedsYourWay to provide members of participating Blue Plans a new home delivery option using Amazon Pharmacy. This new home delivery option with Amazon Pharmacy includes simplified sign-up, real-time medication price displays, as well as an integrated prescription discount card administered by Inside Rx. Covered purchases with the MedsYourWay prescription discount card accrue toward a member’s out of pocket maximums and deductibles.
Inside Rx, which is owned by Express Scripts, provides discounts on both brand and generic medications.
Jarrod Henshaw
“MedsYourWay will challenge the traditional thinking in the PBM industry,” Jarrod Henshaw, senior vice president, chief innovation and supply chain officer for Prime Therapeutics, said in a statement.
Over the coming months, Prime Therapeutics will launch additional services under the MedsYourWay offering.
Amazon acquired PillPack in September 2018, for about $753 million. PillPack provides consumers with their medications in daily packages. In the acquisition, Amazon gained access to PharmacyOS, a software platform created by PillPack to help manage customer’s medications, coordinate refills and renewals.
In November 2020, the company launched Amazon Pharmacy to provide consumers with a way to manage and order prescriptions. In addition, Amazon Prime members without insurance have access to generics at 80% discount and branded therapies at a 40% discount.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
August 1st 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
August 1st 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
August 1st 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More